Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLIM for Cough and Sputum in Acute Upper Respiratory Tract Infection
NCT03827590Phase 3Unknown
- Sponsor
- Sam-A Pharm
- Start
- Nov 2018
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HLIM in acute upper respiratory tract infection (URI) and acute bronchitis, sponsored by Sam-A Pharm. Primary endpoints: Bronchitis Severity Score - Cough Domain at 5 days and Bronchitis Severity Score Total Score at 5 days. Status: unknown.
02
Drugs
HLIM
03
Conditions
acute upper respiratory tract infection (URI)acute bronchitis
Beyond the preview
Go deeper on NCT03827590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827590.